Mitera secures $1.75M to explore pregnancy's immune-tolerance secrets

Mitera Biosciences did not come out of stealth waving its arms. It surfaced the way serious biology does, quietly, deliberately, with receipts. A $1.75 million seed round filed with the SEC, announced December 30, 2025, and a mission rooted in something most of modern immunology forgot to respect. The human body already knows how to tolerate what should not belong. Pregnancy figured it out long before biotech showed up with spreadsheets.

Based in Bellevue, Washington, Mitera Biosciences is building safer alternatives to traditional immunosuppressive therapies for transplant rejection and autoimmune disease by studying that biological ceasefire. During pregnancy, the immune system makes peace without surrendering defense. No broad suppression. No systemic chaos. Just precision. Mitera’s platform is derived from a natural human protein produced by the placenta and expressed in the thymus, designed to increase regulatory T cells while restraining the ones that do the damage. The immune system learns restraint instead of being knocked unconscious.

Kevin Chow, PhD does not chase novelty. He compounds experience. 25 years in biopharma. Founder of Vitaeris. Builder of multinational Phase 3 kidney transplant programs. An acquisition by CSL Behring tends to clarify what matters and what is noise. Mitera reads like the next chapter written by someone who has already paid the tuition for getting it wrong.

Stanley C. Jordan, MD brings the kind of credibility that does not need amplification. Over 400 peer reviewed publications. 3 decades shaping transplant immunology. The first successful ABO incompatible kidney transplant. Architect of IVIG protocols that calm immune response without flattening it. A 2025 Lifetime Achievement Award from the American Society of Transplantation is not a headline, it is a ledger.

S. Ananth Karumanchi, MD connects pregnancy immunology, vascular biology, and kidney disease with the confidence of someone who has published more than 350 times and moved the field forward doing it. An H index of 122 is not trivia. It is influence measured over time.

The clinical problem is blunt. Calcineurin inhibitors keep organs alive but poison the system doing it. Neurotoxicity, nephrotoxicity, metabolic damage, and more than half of kidney transplant patients struggling with intolerance and non adherence. Antibodies form. Grafts fail. Dialysis returns. That is not bad luck. That is a broken approach.

This seed round is not about scale or slogans. It funds IND enabling work, manufacturing and CMC, regulatory strategy, and the protection of exclusive worldwide intellectual property licensed from Cedars Sinai. Mitera is building slowly because immune tolerance does not forgive shortcuts.